Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-03-08
2005-03-08
Kunz, Gary (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S007930, C435S007940, C435S007950, C436S507000
Reexamination Certificate
active
06864062
ABSTRACT:
The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.
REFERENCES:
patent: 5342580 (1994-08-01), Brenner
patent: 5492812 (1996-02-01), Vooheis
patent: 0 909 814 (1999-04-01), None
patent: WO 96 20218 (1996-07-01), None
Foley et al., (1988), “Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease”,Journal of Neurology, vol. 235, pp. 466-471.
Gaskin, “Human Antibodies to Alzheimer's Disease and Normal Neural Elements”,Antibodies to Alzheimer's Disease, pp 137-145.
Gaskin et al., (Jan. 1987), “Autoantibodies To Neurofibrillary Tangles and Brain Tissue in Alzheimer's Disease: Establishment of Epstein-Barr Virus-transformed Antibody-producing Cell Lines”,J. Exp. Med., vol. 165, pp. 245-250.
Lopez et al., (Aug. 1992), “Serum Autoantibodies in Patients With Alzheimer's Disease and Vascular Dementia and in Nondemented Control Subjects”,Stroke, vol. 23, No. 8, pp. 1078-1083.
McRae et al., (Aug. 1993), “Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease”,Behavioural Brain Research, vol. 57, pp. 225-234.
Mecocci et al, (1993), “Antihistone and Anti-dsDNA Autoantibodies in Alzheimer's Disease and Vascular Dementia”,Society of Biological Psychiatry, vol. 33, pp. 380-385.
Mecocci et al., (1995), “Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia”,Journal of Neuroimmunology, vol. 57, pp. 165-170.
Singh et al., (1992), “Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients”,Neuroscience Letters, vol. 147. pp. 25-28.
Singh et al., (1986), “Detection of Brain Autoantibodies in the serum of patients with Alzheimer's disease but not Down's Syndrome”,Immunology Letters, vol. 12, pp. 277-280.
Tanaka et al., (1989), “Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease”,Acta Neurol. Scand., vol. 80, pp. 554-560.
Tchernakov et al., (1992), “Alzheimer's disease and Down's syndrome antibodies bind to the heavy neurofilament protein of cholinergic neurons”,Immunological Factors in Alzheimer's Disease, pp. 670-675.
Schott et al. (Jan. 31, 1996), “Autoantibody reactivity in serum of patients with Alzheimer' disease and other age related dementia”,Psychiatry Res., vol. 50, No. 3, pp. 251-54. (Abstract).
Lopez et al., (Nov. 1991), “Serum auto-antibodies in Alzheimer's disease”Acta Neural Scand, vol. 84, No. 5, pp. 441-44. (Abstract).
Ounanian et al., (1990), “Antibodies to viral antigens, xenoantigens and autoantigens in Alzheimer's disease”.J Clin Lab Anal, vol. 4, No. 5, pp. 367-75. (Abstract).
Loeffler et al, (Feb. 1997), “Immunocytochemical detection of anti-hippocampal antibodies in Alzheimer's disease and normal cerebrospinal fluid”,Neurochem Res., vol. 22, No. 2 pp. 209-14. (Abstract).
McRae et al., (May-Aug. 1996), “Microglial Cerebrospinal fluid antibodies. Significance for Alzheimer disease”,Mol. Chem. Neuropathol, vol. 28, No. 1-3, pp. 89-95. (Abstract).
Dahlstrom et al., (Aug.-Dec. 1994), “Alzheimer's disease cerebrospinal fluid antibodies display selectivity for Microglia. Investigations with cell cultures and human cortical biopsies”Mol Neurobiol, vol. 9, No. 1-3, pp. 41-54. (Abstract).
Dahlstrom et al., (1990), “8investigations on auto-antibodies in Alzheimer's and Parkinson's disease, using defined neuronal cultures”J Neural Transm Suppl., vol. 29, 195-206. (Abstract).
Sugiura et al., (Jan. 1989), “Detection of anti-cerebral autoantibodies in schizophrenia and Alzheimer's disease”J Clin lab Immunol, vol. 28, No. 1, pp. 1-3. (Abstract).
Bahmanyar et al., (Oct. 1983), “Serum antibodies to neurofilament antigens in patients with neurological and other diseases and in healthy controls”,J. Neuroimmunal, vol. 5, No. 2, pp. 191-196. (Abstract).
Genovesi et al., (Mar. 1996), “Relationship between autoimmune thyroid disease Rand Alzheimer's disease”,Panminerva Med., vol. 38, No. 1, pp. 61-63. (Abstract).
Serot et al., (Sep. 1992), “Antibodies to choroids plexus in senile dementia of Alzheimer's type”J Clin Pathol, vol. 45, No. 9, pp. 781-783. (Abstract).
Singh et al., (1989) “Increase of immunoglobin G3 subclass is related to brain autoantibody in Alzheimer's disease but not in Down's syndrome”,Autoimmunity, vol. 3, No. 2, pp. 95-101. (Abstract).
Kumar et al., (1988) “Serum IgG Brain reactive antibodies in Alzheimer disease and Down syndrome”,Alzheimer Dis. Assoc. Disord, vol. 2, No. 1, pp. 50-55. (Abstract).
Fransceschi et al., (Jul. 1989), “Neuron-binding antibodies in Alzheimer's Disease and Down's syndrome”,J. Gerontol, vol., 44, No. 4, pp. 128-30. (Abstract).
Mecocci et al., (Sep. 1992), “Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias”Brain Behav Immun, vol. 6, No. 3, pp. 286-92. (Abstract).
Heinonen et al., (Jan. 1993), “Circulating immune complexes in sera from patients with Alzheimer's disease, multi-infaracct dementia and Down's syndrome”,Neurosci Lett, vol. 149, No. 1, pp. 67-70. (Abstract).
Ryskova et al., (1998), “Serum antibodies against brain tissue in patients with multiple sclerosis”, Sb Ved Pr Lek Fak Karlovy University HNradcy Kralove Suppl., vol. 31, No. 4, pp. 407-11. (Abstract).
Henneberg et al., (Nov. 1991), “Antibodies to brain tissue in sera of patients with chronic progressive multiple sclerosis”,J Neuroimmunol, vol. 34, No. 2-3, pp. 223-27. (Abstract).
Hassin-Baer et al., (Mar. 1992), “Antibodies from Down's syndrome patients bind to the same cholinergin neurofilament protein recognized by Alzheimer's disease antibodies”,Neurology, vol. 42, No. 3, pp. 551-55. (Abstract).
Vazquez et al., (Aug. 1996), “Antibodies to human brain spectrin in Alzheimer's disease.”J Neuroimmunol, vol. 68, No. 1-2, pp. 39-144. (Abstract).
Fillit et al., (Mar. 1987, “Antivascular antibodies in the sera of patients with senile demential of the Alzheimer's type”,J Gerontol, vol. 42, No. 2, pp. 182-184 (Abstract).
David M. Wilson et al., “Free fatty acids stimulate the polymerization of tau and amyloid beta peptides: In vitro evidence for a common effector of pathogenesis in Alzheimer's disease”,American Journal of Pathology, vol. 150, No. 6, (1997), pp. 2181-2195. XP000952986.
Shi Du Yan et al., “Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid.beta.-peptide”,Nature Medicine, (1995) 1/7, (693-699). XP002151418.
Mark P. Mattson et al., “4-Hydroxynonenal, a product of lipid peroxidatin, inhibits dephosphorylation of the microtubule-associated protein tau”,Neuroreport, vol. 8, No. 9-10, 1997, pp. 2275-2281. XP000953016.
Data Base Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; 1990, Ksiezak-R
Davies Peter
DeBernardis John F.
Kerkman Daniel J.
Kohnken Russell E.
Zinkowski Raymond P.
Gucker Stephen
Kunz Gary
McDonnell Boehnen & Hulbert & Berghoff LLP
Molecular Geriatrics Corporation
LandOfFree
Purified antigen for Alzheimer's disease and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified antigen for Alzheimer's disease and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified antigen for Alzheimer's disease and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439578